Lihsyng Stanford Lee, Age 79Kissimmee, FL
Lihsyng Lee Phones & Addresses
Kissimmee, FL
Foster City, CA
109 Einstein Way, Cranbury, NJ 08512 (609) 448-7083
East Windsor, NJ
Trenton, NJ
Bridgewater, NJ
West Windsor, NJ
109 Einstein Way, East Windsor, NJ 08512
Work
Position:
Professional/Technical
Education
Degree:
Graduate or professional degree
Mentions for Lihsyng Stanford Lee
Publications & IP owners
Us Patents
Single-Chain Antigen-Binding Proteins Capable Of Glycosylation, Production And Uses Thereof
US Patent:
6743896, Jun 1, 2004
Filed:
Sep 20, 2001
Appl. No.:
09/956086
Inventors:
David Filpula - Piscataway NJ
Maoliang Wang - E. Brunswick NJ
Robert Shorr - Edison NJ
Marc Whitlow - El Sobrante CA
Lihsyng S. Lee - Princeton Junction NJ
Maoliang Wang - E. Brunswick NJ
Robert Shorr - Edison NJ
Marc Whitlow - El Sobrante CA
Lihsyng S. Lee - Princeton Junction NJ
Assignee:
Enzon, Inc. - Bridgewater NJ
International Classification:
C07K 1600
US Classification:
5303873, 5303911, 5303917, 435188
Abstract:
The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.
Single-Chain Antigen-Binding Proteins Capable Of Glycosylation, Production And Uses Thereof
US Patent:
6743908, Jun 1, 2004
Filed:
Sep 20, 2001
Appl. No.:
09/956087
Inventors:
David Filpula - Piscataway NJ
Maoliang Wang - E. Brunswick NJ
Robert Shorr - Edison NJ
Marc Whitlow - El Sobrante CA
Lihsyng S. Lee - Princeton Junction NJ
Maoliang Wang - E. Brunswick NJ
Robert Shorr - Edison NJ
Marc Whitlow - El Sobrante CA
Lihsyng S. Lee - Princeton Junction NJ
Assignee:
Enzon, Inc. - Bridgewater NJ
International Classification:
C07H 2104
US Classification:
536 2353, 435 691, 435 696, 4353201
Abstract:
The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.
Polyalkylene Oxide-Modified Single Chain Polypeptides
US Patent:
6824782, Nov 30, 2004
Filed:
Feb 26, 2001
Appl. No.:
09/791540
Inventors:
Marc Whitlow - El Sobrante CA
Robert G. L. Shorr - Edison NJ
David R. Filpula - Piscataway NJ
Lihsyng Stanford Lee - Princeton Junction NJ
Robert G. L. Shorr - Edison NJ
David R. Filpula - Piscataway NJ
Lihsyng Stanford Lee - Princeton Junction NJ
Assignee:
Enzon, Inc. - Piscataway NJ
International Classification:
A61K 39395
US Classification:
4241781, 5303891, 5303911
Abstract:
The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
Polyalkylene Oxide-Modified Single Chain Polypeptides
US Patent:
6872393, Mar 29, 2005
Filed:
Feb 26, 2001
Appl. No.:
09/791578
Inventors:
Marc Whitlow - El Sobrante CA, US
Robert G. L. Shorr - Edison NJ, US
David R. Filpula - Piscataway NJ, US
Lihsyng Standford Lee - Princeton Junction NJ, US
Robert G. L. Shorr - Edison NJ, US
David R. Filpula - Piscataway NJ, US
Lihsyng Standford Lee - Princeton Junction NJ, US
Assignee:
Enzon, Inc. - Piscataway NJ
International Classification:
A61K039/395
C07K016/46
C07K016/46
US Classification:
4241781, 5303911
Abstract:
The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
Polyalkylene Oxide-Modified Single Chain Polypeptides
US Patent:
7150872, Dec 19, 2006
Filed:
Aug 10, 2004
Appl. No.:
10/915069
Inventors:
Marc Whitlow - El Sobrante CA, US
Robert G. L. Shorr - Edison NJ, US
David R. Filpula - Piscataway NJ, US
Lihsyng Standford Lee - Princeton Junction NJ, US
Robert G. L. Shorr - Edison NJ, US
David R. Filpula - Piscataway NJ, US
Lihsyng Standford Lee - Princeton Junction NJ, US
Assignee:
Enzon, Inc. - Piscataway NJ
International Classification:
A61K 39/40
C07K 16/00
C12Q 1/68
C07K 16/00
C12Q 1/68
US Classification:
4241781, 5303891, 5303911
Abstract:
The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
Polyalkylene Oxide-Modified Single Chain Polypeptides
US Patent:
7632504, Dec 15, 2009
Filed:
Aug 2, 2004
Appl. No.:
10/909948
Inventors:
Marc Whitlow - El Sobrante CA, US
Robert G. L. Shorr - Edison NJ, US
David R. Filpula - Piscataway NJ, US
Lihsyng Standford Lee - Princeton Junction NJ, US
Robert G. L. Shorr - Edison NJ, US
David R. Filpula - Piscataway NJ, US
Lihsyng Standford Lee - Princeton Junction NJ, US
Assignee:
Enzon, Inc. - Bridgewater NJ
International Classification:
A61K 39/00
C07K 17/00
C07K 16/00
C07K 17/00
C07K 16/00
US Classification:
4241781, 5303911, 5303871
Abstract:
The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
Production Of Bispecific Molecules Using Polyethylene Glycol Linkers
US Patent:
2006015, Jul 13, 2006
Filed:
Sep 16, 2003
Appl. No.:
10/527936
Inventors:
Nehal Mohamed - Bud Lake NJ, US
Leslie Casey - Newyork NY, US
James Porter - Sparta NJ, US
Xiaoliang Wang - Pine Brook NJ, US
Muctarr Sesay - Margate FL, US
Lihsyng Lee - Bridgewater NJ, US
Leslie Casey - Newyork NY, US
James Porter - Sparta NJ, US
Xiaoliang Wang - Pine Brook NJ, US
Muctarr Sesay - Margate FL, US
Lihsyng Lee - Bridgewater NJ, US
Assignee:
EluSys Therapeutics, Inc. - Pine Brook NJ
International Classification:
A61K 39/40
C07K 16/12
C07K 16/12
US Classification:
424143100, 424164100, 530388400
Abstract:
The invention relates to a bispecific molecule comprising a first recognition binding moeity that binds a Cab-like receptor cross-linked using a poly-(ethylene glycol) (“PEG”) linker with one or more second recognition binding moieties that bind a molecule. The invention also relates to methods of producing such bispecific molecules and to therapeutic uses of such bispecific molecules.
Modified Erythropoietin
US Patent:
2010018, Jul 22, 2010
Filed:
Jul 16, 2007
Appl. No.:
12/376333
Inventors:
Abraham Abuchowski - Califon NJ, US
Lihsyng Stanford Lee - Cranbury NJ, US
Lihsyng Stanford Lee - Cranbury NJ, US
Assignee:
PROLONG PHARMACEUTICALS, INC. - Monmouth Junction NJ
International Classification:
A61K 38/18
C07K 14/505
A61P 7/00
C07K 14/505
A61P 7/00
US Classification:
514 12, 530380
Abstract:
This invention relates to novel protein conjugates, in particular, to novel pegylated proteins, and their methods of making and use. One aspect of the present invention relates to pegylated-erythropoietin having greater clinical efficacy and stability during shipment and storage than current erythropoietin formulations.
Possible Relatives
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.